Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

corcept therapeutics - CORT

CORT

Close Chg Chg %
90.21 1.40 1.55%

Closed Market

91.61

+1.40 (1.55%)

Volume: 1.17M

Last Updated:

Jul 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: corcept therapeutics - CORT

CORT Key Data

Open

$90.29

 Day Range

89.73 - 92.83

52 Week Range

28.66 - 92.83

 Market Cap

$9.68B

Shares Outstanding

107.35M

 Public Float

94.69M

Beta

0.46

 Rev. Per Employee

N/A

P/E Ratio

257.74

 EPS

$0.45

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.03M

  

CORT Performance

1 Week
 
 1.55%
 
1 Month
 
 26.15%
 
3 Months
 
 118.59%
 
1 Year
 
 26.76%
 
5 Years
 
 315.65%
 

CORT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6
Full Ratings ➔

About corcept therapeutics - CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

CORT At a Glance

Corcept Therapeutics, Inc.
101 Redwood Shores Parkway
Redwood City, California 94065
Phone 1-650-327-3270 Revenue 761.41M
Industry Pharmaceuticals: Major Net Income 98.17M
Sector Health Technology 2025 Sales Growth 12.794%
Fiscal Year-end 12 / 2026 Employees 730
View SEC Filings

CORT Valuation

P/E Current 257.743
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 42.532
Price to Sales Ratio 5.484
Price to Book Ratio 5.692
Price to Cash Flow Ratio 29.41
Enterprise Value to EBITDA 81.597
Enterprise Value to Sales 5.003
Total Debt to Enterprise Value 0.002

CORT Efficiency

Revenue/Employee 1,043,023.288
Income Per Employee 134,480.822
Receivables Turnover 11.918
Total Asset Turnover 0.907

CORT Liquidity

Current Ratio 2.893
Quick Ratio 2.815
Cash Ratio 2.241

CORT Profitability

Gross Margin 98.296
Operating Margin 5.883
Pretax Margin 8.729
Net Margin 12.893
Return on Assets 11.697
Return on Equity 14.792
Return on Total Capital 15.013
Return on Invested Capital 14.669

CORT Capital Structure

Total Debt to Total Equity 0.943
Total Debt to Total Capital 0.934
Total Debt to Total Assets 0.729
Long-Term Debt to Equity 0.775
Long-Term Debt to Total Capital 0.768
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Corcept Therapeutics - CORT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
401.86M 482.38M 675.04M 761.41M
Sales Growth
+9.80% +20.04% +39.94% +12.79%
Cost of Goods Sold (COGS) incl D&A
5.38M 6.48M 10.88M 12.98M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.97M 1.04M 1.34M 1.89M
Depreciation
2.97M 1.04M 1.34M 1.89M
Amortization of Intangibles
- - - -
-
COGS Growth
+1.97% +20.35% +67.91% +19.25%
Gross Income
396.47M 475.89M 664.16M 748.43M
Gross Income Growth
+9.92% +20.03% +39.56% +12.69%
Gross Profit Margin
+98.66% +98.66% +98.39% +98.30%
2022 2023 2024 2025 5-year trend
SG&A Expense
283.84M 368.61M 527.21M 703.63M
Research & Development
130.99M 184.35M 246.89M 254.91M
Other SG&A
152.85M 184.26M 280.32M 448.73M
SGA Growth
+20.16% +29.87% +43.02% +33.46%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
112.63M 107.28M 136.95M 44.80M
Non Operating Income/Expense
3.56M 17.27M 24.54M 21.67M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
116.19M 124.56M 161.49M 66.46M
Pretax Income Growth
-7.05% +7.20% +29.65% -58.84%
Pretax Margin
+28.91% +25.82% +23.92% +8.73%
Income Tax
14.77M 18.42M 20.28M (33.19M)
Income Tax - Current - Domestic
48.65M 47.85M 60.22M 3.19M
Income Tax - Current - Foreign
30.00K 56.00K 256.00K 1.16M
Income Tax - Deferred - Domestic
(33.44M) (28.26M) (39.63M) (36.71M)
Income Tax - Deferred - Foreign
(469.00K) (1.24M) (564.00K) (824.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
(130.00K) (644.00K) (1.48M) (1.48M)
Consolidated Net Income
101.29M 105.50M 139.73M 98.17M
Minority Interest Expense
- - - -
-
Net Income
101.29M 105.50M 139.73M 98.17M
Net Income Growth
-9.98% +4.15% +32.45% -29.74%
Net Margin Growth
+25.20% +21.87% +20.70% +12.89%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
101.29M 105.50M 139.73M 98.17M
Preferred Dividends
- - - -
-
Net Income Available to Common
101.29M 105.50M 139.73M 98.17M
EPS (Basic)
0.9485 1.0187 1.3536 0.9452
EPS (Basic) Growth
-2.50% +7.40% +32.88% -30.17%
Basic Shares Outstanding
106.79M 103.56M 103.23M 103.86M
EPS (Diluted)
0.8734 0.9441 1.2313 0.8182
EPS (Diluted) Growth
-2.22% +8.09% +30.42% -33.55%
Diluted Shares Outstanding
115.97M 111.74M 113.48M 119.99M
EBITDA
115.60M 108.32M 138.29M 46.69M
EBITDA Growth
-9.36% -6.30% +27.66% -66.24%
EBITDA Margin
+28.77% +22.46% +20.49% +6.13%

Snapshot

Average Recommendation BUY Average Target Price 92.50
Number of Ratings 6 Current Quarters Estimate 0.235
FY Report Date 09 / 2026 Current Year's Estimate 0.586
Last Quarter’s Earnings 0.03 Median PE on CY Estimate N/A
Year Ago Earnings 0.82 Next Fiscal Year Estimate 2.614
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 4 5
Mean Estimate 0.23 0.56 0.59 2.61
High Estimates 0.34 0.79 0.80 5.38
Low Estimate 0.08 0.20 0.17 0.32
Coefficient of Variance 50.34 47.49 48.29 77.56

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 4
OVERWEIGHT 0 0 0
HOLD 1 1 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Corcept Therapeutics - CORT

Date Name Shares Transaction Value
Mar 5, 2026 Joseph K. Belanoff Chief Executive Officer; Director 460,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Atabak Mokari Chief Financial Officer 140,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Sean Maduck See Remarks 140,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Joseph Douglas Lyon See Remarks 140,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 George Leonard Baker Director 3,308,303 Bona fide gift 0.00
Aug 13, 2025 Daniel N. Swisher Director 2,200 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.08 per share 30,976.00
Aug 13, 2025 Daniel N. Swisher Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $72.3 per share 0.00
Aug 13, 2025 Daniel N. Swisher Director 5,500 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 William Guyer Chief Development Officer 40,494 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $21.65 per share 876,695.10
Aug 13, 2025 William Guyer Chief Development Officer 5,487 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.77 per share 393,801.99
Aug 13, 2025 William Guyer Chief Development Officer 350,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Corcept Therapeutics in the News